Ibritumomab tiuxetan
Ibritumomab Tiuxetan (pronounced as eye bri too moe' mab tye ux' e tan) is a monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. It is marketed under the trade name Zevalin.
Etymology
The name "Ibritumomab Tiuxetan" is derived from the components of the drug. "Ibri" is an abbreviation for the company that developed the drug, IDEC Pharmaceuticals. "Tumomab" indicates that it is a tumor-targeting monoclonal antibody. "Tiuxetan" refers to the chelator that is used to attach the radioactive isotope to the antibody.
Usage
Ibritumomab Tiuxetan is used to treat patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma, including patients with rituximab-refractory follicular non-Hodgkin lymphoma.
Mechanism of Action
Ibritumomab Tiuxetan is a radioimmunotherapy agent. It consists of a monoclonal antibody that targets the CD20 antigen on the surface of B-cells, and a radioactive isotope (Yttrium-90 or Indium-111), which delivers a dose of radiation to the targeted cells.
Side Effects
Common side effects of Ibritumomab Tiuxetan include anemia, neutropenia, thrombocytopenia, fever, and infection. Severe side effects may include myelodysplastic syndrome and leukemia.
Related Terms
- Monoclonal antibody
- Non-Hodgkin lymphoma
- Radioimmunotherapy
- Anemia
- Neutropenia
- Thrombocytopenia
- Fever
- Infection
- Myelodysplastic syndrome
- Leukemia
External links
- Medical encyclopedia article on Ibritumomab tiuxetan
- Wikipedia's article - Ibritumomab tiuxetan
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski